Dr. Pothuri on PARP Inhibitors for Ovarian Cancer

Bhavana Pothuri, MD
Published: Monday, Oct 30, 2017



Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

There is a need for new agents, says Pothuri, and PARP inhibitors are a new class of agents that are now approved. The first PARP inhibitor that was approved was olaparib (Lynparza) in December 2014. Olaparib is approved in patients with recurrent ovarian cancer who have had 3 or more prior lines of therapy, and are BRCA-mutation carriers.

It is a very exciting time for PARP inhibitors, states Pothuri. PARP inhibitors are showing promise utilized in ovarian cancer accounts for only about 20% of gynecologic malignancies, but it accounts for over 50% of gynecologic cancer deaths.
 


Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

There is a need for new agents, says Pothuri, and PARP inhibitors are a new class of agents that are now approved. The first PARP inhibitor that was approved was olaparib (Lynparza) in December 2014. Olaparib is approved in patients with recurrent ovarian cancer who have had 3 or more prior lines of therapy, and are BRCA-mutation carriers.

It is a very exciting time for PARP inhibitors, states Pothuri. PARP inhibitors are showing promise utilized in ovarian cancer accounts for only about 20% of gynecologic malignancies, but it accounts for over 50% of gynecologic cancer deaths.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x